35 citations
,
January 2004 in “European journal of oncology nursing” In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.
14 citations
,
October 2003 in “Annals of Oncology” In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.
The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.